H.C. Wainwright has reiterated its Buy rating on Anixa Biosciences (NASDAQ: ANIX), maintaining a $7 price target, in a note published this week. The US investment bank's continued endorsement signals confidence in the biotech firm's pipeline, particularly its experimental cancer vaccines targeting difficult-to-treat tumours.
Anixa, headquartered in California, focuses on novel immunotherapy approaches. Its lead candidate, a vaccine for triple-negative breast cancer, is in early clinical trials. The company also has a partnership with the Cleveland Clinic to develop a vaccine for ovarian cancer. While the science is promising, the stock remains highly speculative and is not yet profitable.
For UK investors with exposure to US-listed biotech stocks through diversified portfolios or pension funds, the reiteration provides a snapshot of analyst sentiment in a volatile sector. However, H.C. Wainwright's target price of $7 implies significant upside from current levels, which trade well below that figure. The stock has faced pressure this year amid broader market volatility and risk-off sentiment toward pre-revenue biotech companies.
Analysts caution that early-stage biotech investments carry substantial risk. Clinical trial failures, regulatory hurdles, and funding needs can all impact share prices. H.C. Wainwright's view is just one of several; investors should consider a range of sources before making decisions.
The broader biotech sector has seen mixed performance in 2025, with interest rate expectations and M&A activity influencing valuations. For UK pension holders, the indirect exposure via global equity funds means such analyst notes are more relevant as sentiment indicators than direct trading signals.
Source: H.C. Wainwright research note